Canaccord Genuity analyst William Plovanic maintained a Buy rating on TransMedics Group yesterday and set a price target of $124.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
William Plovanic has given his Buy rating due to a combination of factors pointing to durable growth despite a softer transplant backdrop. He notes that April’s aviation data showed record flight hours and higher daily flights for TransMedics’ logistics network, which he views as strong evidence that procedure volumes on the company’s platform remain robust and closely tied to expanding DCD activity.
He also emphasizes that, even though total U.S. transplant counts dipped, DCD liver volumes continued to grow at a double‑digit pace and DCD heart and lung procedures still increased, underscoring the company’s central role in this segment. Plovanic highlights that his revenue and logistics forecasts for Q2 remain intact, supports an unchanged $124 price target, and believes the current data set validates continued upside for TransMedics as it expands in DCD-enabled organ transplantation and related services.
In another report released on May 6, Piper Sandler also maintained a Buy rating on the stock with a $120.00 price target.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMDX in relation to earlier this year.